Vertex Pharmaceuticals Incorpor (VRTX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Vertex Pharmaceuticals Incorpor

NasdaqGS•Healthcare•Biotechnology

$516.34+3.08(0.01%)After hours

Market Cap

$130.21B

P/E

29.6x

P/S

10.3x

P/B

6.4x

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

How this company scores

ExcellentMetricSide Score: 81/100

Strongest: Growth (23/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability22/25

Growth23/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality21/25

Strengths

Strong marginsHigh ROERising earningsInterest easily covered

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 29.6x5y range 26.0x – 57.0x

Currently near its 16-quarter median.

P/S · 10.3x5y range 8.6x – 17.4x

Currently near its 20-quarter median.

P/B · 6.4x5y range 5.8x – 13.0x

Price & Volume

Market Cap $130.21B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $12.59B
Q. Revenue: $3.33B
TTM EBITDA: $5.00B
TTM Op. Income: $4.78B
Q. Op. Income: $1.25B
TTM Net Income: $4.41B
Q. Net Income: $1.10B
EPS: $4.34
Shares Out.: $253.70M

$12.59B in TTM revenue grew 10.2% YoY, reaching $3.33B last quarter. TTM EBITDA of $5.00B and TTM operating income of $4.78B show growth is flowing through to the bottom line. TTM net income of $4.41B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 39.1%
Op. Margin: 37.4%
Net Margin: 33.0%

Op. margin of 37.4% is down 1.4% YoY — costs are rising relative to revenue. Net margin at 33.0% Over the past year, operating margin is down 4% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 29.6x
P/S Ratio: 10.3x
P/B Ratio: 6.4x

At 29.6x P/E, the stock trades within typical market levels. P/S of 10.3x and P/B of 6.4x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 6% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $27.42B
Cash: $6.14B
Long-Term Debt: N/A
Book Value: $20.25B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.13B
TTM Free Cash Flow: $3.80B
FCF Margin: 30.2%
FCF / Net Income: 0.9

TTM FCF of $3.80B on $1.13B in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.